Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the… bypharmanewsdailyJanuary 30, 2019